Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Mem. Inst. Oswaldo Cruz ; 108(6): 730-734, set. 2013. tab, graf
Article in English | LILACS | ID: lil-685488

ABSTRACT

Intrathecal synthesis of human T-lymphotropic virus type 1 (HTLV-1) antibodies (Abs) represents conclusive evidence of a specific immune response in the central nervous system of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Western blotting (WB) for HTLV Abs in serum is a confirmatory test for HTLV-1 infection. The aim of this study was to standardise the Western blot to demonstrate the intrathecal pattern of Abs against HTLV-1 proteins in HAM/TSP patients. Paired cerebrospinal fluid (CSF) and serum samples were selected from 20 patients with definite HAM/TSP, 19 HTLV-1 seronegative patients and two HTLV-1 patients without definite HAM/TSP. The presence of reactive bands of greater intensity in the CSF compared to serum (or bands in only the CSF) indicated the intrathecal synthesis of anti-HTLV-1 Abs. All definite HAM/TSP patients presented with an intrathecal synthesis of anti-HTLV-1 Abs; these Abs were not detected in the control patients. The most frequent intrathecal targets of anti-HTLV-1 Abs were GD21, rgp46-I and p24 and, to a lesser extent, p19, p26, p28, p32, p36, p53 gp21 and gp46. The intrathecal immune response against env (GD21 and rgp46-I) and gag (p24) proteins represents the most important humoral pattern in HAM/TSP. This response may be used as a diagnostic marker, considering the frequent association of intrathecal anti-HTLV-1 Ab synthesis with HAM/TSP and the pathogenesis of this neurological disease.


Subject(s)
Humans , Antibodies, Viral , Blotting, Western/standards , Central Nervous System/immunology , Human T-lymphotropic virus 1/immunology , Paraparesis, Tropical Spastic/immunology , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , Central Nervous System/metabolism , Enzyme-Linked Immunosorbent Assay , Gene Products, env/immunology , Gene Products, gag/immunology , Immunoglobulin G/blood , Immunoglobulin G/cerebrospinal fluid , Paraparesis, Tropical Spastic/blood , Paraparesis, Tropical Spastic/cerebrospinal fluid , Sensitivity and Specificity
2.
Mem. Inst. Oswaldo Cruz ; 102(6): 741-749, Sept. 2007. tab
Article in English | LILACS | ID: lil-463482

ABSTRACT

This study was carried out to evaluate the molecular pattern of all available Brazilian human T-cell lymphotropic virus type 1 Env (n = 15) and Pol (n = 43) nucleotide sequences via epitope prediction, physico-chemical analysis, and protein potential sites identification, giving support to the Brazilian AIDS vaccine program. In 12 previously described peptides of the Env sequences we found 12 epitopes, while in 4 peptides of the Pol sequences we found 4 epitopes. The total variation on the amino acid composition was 9 and 17 percent for human leukocyte antigen (HLA) class I and class II Env epitopes, respectively. After analyzing the Pol sequences, results revealed a total amino acid variation of 0.75 percent for HLA-I and HLA-II epitopes. In 5 of the 12 Env epitopes the physico-chemical analysis demonstrated that the mutations magnified the antigenicity profile. The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope. Besides, the analysis of selection pressure have found 8 positive selected sites (w = 9.59) using the codon-based substitution models and maximum-likelihood methods. These studies underscore the importance of this Env region for the virus fitness, for the host immune response and, therefore, for the development of vaccine candidates.


Subject(s)
Humans , Drug Design , Epitope Mapping , Gene Products, env/genetics , Human T-lymphotropic virus 1/genetics , Human T-lymphotropic virus 1/immunology , Retroviridae Proteins, Oncogenic/genetics , Viral Vaccines , Amino Acid Sequence , Base Sequence , Gene Products, env/immunology , Retroviridae Proteins, Oncogenic/immunology
3.
Rev. Soc. Bras. Med. Trop ; 40(3): 277-281, maio-jun. 2007. ilus
Article in Portuguese | LILACS | ID: lil-456319

ABSTRACT

O HTLV-1 é o vírus causador da leucemia/linfoma de célula T no adulto e de uma desordem neurológica conhecida por mielopatia associada ao HTLV ou paraparesia espástica tropical. Um dos modos de transmissão é pelo sangue contaminado e seus subprodutos e, devido ao risco de infecções associadas ao HTLV sua pesquisa na triagem de doadores de sangue foi introduzida no Brasil a partir de 1993. Os kits diagnósticos utilizados nos bancos de sangue nacionais são na sua maioria comprados de empresas estrangeiras. O Brasil não detém a tecnologia para produção deste material e há a necessidade de produção de sistemas de diagnóstico com tecnologia nacional. Neste trabalho, mostramos a expressão da gp21/HTLV-1 em Escherichia coli e sua reatividade frente a anticorpos monoclonais e de pacientes infectados. Expressar tais proteínas é o primeiro passo para obtenção de conjuntos diagnósticos com tecnologia brasileira.


HTLV-1 is the virus that causes T cell lymphoma/leukemia in adults and a neurological disorder known as HTLV-associated myelopathy or tropical spastic paraparesis. One of the transmission means is through contaminated blood and its byproducts. Because of the risk of HTLV-associated infections, screening for HTLV was introduced for Brazilian blood donors in 1993. Most of the diagnostic kits used in the national blood banks are bought from foreign companies. Brazil does not have the technology to produce this material and there is a need to produce diagnostic systems with national technology. In this study, we show the expression of gp21/HTLV-1 in Escherichia coli and its reactivity towards monoclonal antibodies and the antibodies of infected patients. Expressing these proteins is the first step towards obtaining diagnostic kits with Brazilian biotechnology.


Subject(s)
Humans , Cloning, Molecular , Gene Products, env/chemistry , Human T-lymphotropic virus 1/chemistry , Retroviridae Proteins, Oncogenic/genetics , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/immunology , Escherichia coli/genetics , Escherichia coli/metabolism , Gene Expression , Genetic Vectors , Gene Products, env/genetics , Gene Products, env/immunology , HTLV-I Antibodies/genetics , HTLV-I Antibodies/immunology , Human T-lymphotropic virus 1/genetics , Human T-lymphotropic virus 1/immunology , Immunoblotting , Polymerase Chain Reaction , Retroviridae Proteins, Oncogenic/isolation & purification
4.
Indian J Dermatol Venereol Leprol ; 2006 Jan-Feb; 72(1): 8-18
Article in English | IMSEAR | ID: sea-52736

ABSTRACT

Development of a preventive vaccine for HIV is the best hope of controlling the AIDS pandemic. HIV has, however, proved a difficult pathogen to vaccinate against because of its very high mutation rate and capability to escape immune responses. Neutralizing antibodies that can neutralize diverse field strains have so far proved difficult to induce. Adjuvanting these vaccines with cytokine plasmids and a "prime-boost," approach is being evaluated in an effort to induce both CTL and antibody responses and thereby have immune responses active against both infected cells and free viral particles, thereby necessitating fewer doses of recombinant protein to reach maximum antibodies titers. Although obstacles exist in evaluation of candidate HIV vaccines, evidence from natural history studies, new molecular tools in virology and immunology, new adjuvants, new gene expression systems, new antigen delivery systems, recent discoveries in HIV entry and pathogenesis, and promising studies of candidate vaccines in animal models have provided reasons to hope that developing a safe and effective AIDS vaccine is possible and within reach.


Subject(s)
AIDS Vaccines/immunology , Antibody Formation , Clinical Trials as Topic , Gene Products, env/immunology , HIV Antigens , HIV Infections/immunology , HIV-1/immunology , Humans , Immunity, Cellular , Research , T-Lymphocytes/immunology , T-Lymphocytes, Cytotoxic/immunology , Vaccines, Synthetic/immunology
5.
Asian Pac J Allergy Immunol ; 2001 Dec; 19(4): 259-65
Article in English | IMSEAR | ID: sea-36921

ABSTRACT

The potential factors of resistance to HIV-1 infection were investigated in 23 HIV discordantly infected couples, of each, one partner had HIV infection and the matched spouse was not infected. Both partners of the HIV discordant couples possessed comparable number of CD4+ cells expressing CCR5. Our study demonstrated that resistance to HIV-1 infection was not due to low level of HIV viral load in their infected-matched spouses. In addition, selective biological phenotype of HIV clinical isolates, which is indicative for risk of transmission, could not be determined in this study. However, we have demonstrated that the unknown genetic factor(s), and neutralizing antibody of broad and high activity could be taken into an account for resistance to HIV infection in the HIV discordant couples.


Subject(s)
Antibodies/blood , Disease Transmission, Infectious , Female , Gene Products, env/immunology , Genetic Predisposition to Disease , HIV Infections/genetics , HIV Seronegativity , HIV Seropositivity , HIV-1/immunology , Heterosexuality , Humans , Male , Neutralization Tests , Spouses , Thailand , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL